T cells
Researchers at Weill Cornell Medicine have found that engineered T cells have shown promise in cancer treatment, but may also recognize off-target epitopes, causing severe toxicities. The study, published in the journal Molecular Therapy, suggests that a genetic screen of 3,000 proteomic epitopes in the MHC-I ligandome uncovered off-target
T cells
New research by a team of scientists from the University of Wisconsin Madison has made significant strides in predicting T cell receptor (TCR) activation. The study, which has been peer-reviewed, is based on a comprehensive database of 22,000 TCR-peptide pairs, centered around 25 immunogenic human and mouse epitopes, across
T cells
Research conducted at Gyeongsang National University in South Korea has shed light on the optimal priming conditions for canine mesenchymal stem cells (cAMSCs), which have been widely studied for their immunomodulatory abilities in treating immune-mediated diseases. The study, funded by the National Research Foundation (NRF) of Korea, aimed to investigate
Biochemistry
Research conducted at Nanjing Medical University has led to the identification of CCR4 memory Tregs and PD-1 T cells as potential biomarkers for diagnosing active tuberculosis. The study, which enrolled 140 patients with active tuberculosis and 140 healthy controls, found that these cell subsets were associated with TB infection and
T cells
Researchers at Mayo Clinic Arizona have made significant progress in addressing the limitations of chimeric antigen receptor (CAR) T cell therapy in treating solid tumors. The study, published in Frontiers in Immunology, introduces a new class of engineered receptors that modulate T cell activity independently of direct antigen recognition. Chimeric
Cancer
Research conducted at the Institute for Biomedical Engineering in Tianjin, China, has led to the development of nanoparticles that can reprogram tumor-associated macrophages to fight cancer. The study, published in Biomaterials Science, shows that the nanoparticles can induce immunogenic cell death of tumor cells, activate dendritic cells, and initiate T
Cancer
Researchers at Mayo Clinic Arizona have made significant progress in addressing the limitations of chimeric antigen receptor (CAR) T cell therapy in treating solid tumors. The study, published in Frontiers in Immunology, introduces a new class of engineered receptors that modulate T cell activity independently of direct antigen recognition. Chimeric
Cancer
Researchers from the University of Texas MD Anderson Cancer Center have made a significant discovery in the field of cancer therapy, developing a new technique to target collagen in tumors. The study, published in the Proceedings of the National Academy of Sciences, found that a specific type of T cell
Cancer
Researchers at Guangzhou University of Chinese Medicine have made a significant discovery in the field of cancer immunotherapy. A new customized immunomodulator, developed by the team, has been shown to comprehensively reinforce the anti-tumor immunological cascade. This breakthrough has the potential to enhance the efficacy of immunotherapy for cold tumors,
Cancer
A new study published in the Journal of Managed Care & Specialty Pharmacy has examined the real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals. The research, conducted by investigators at Memorial Sloan-Kettering Cancer Center, analyzed data from the Premier Healthcare
Cancer
Cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) have made a groundbreaking discovery about the underlying mechanisms of immune system stress response to protein misfolding, which could revolutionize cancer immunotherapy treatment. The study,
Vaccines
Researchers from Soochow University have made a significant discovery in the field of cancer vaccines, detailing a novel strategy to enhance the efficacy of immunotherapy. By developing a nanovesicle-based approach, they have found that loading tyrosine kinase inhibitors (TKIs) into these tiny vesicles can increase Major-Histocompatibility-Complex I (MHC I) expression
